We are happy to share that our client, Antoxerene, Inc., just received a $1.5 million investment to further develop technology that will help identify potential new pharmaceuticals for cancer and cellular-aging treatments.
One of our specialties at Newman & Lickstein, LLP is helping life science & biotechnology professionals navigate through the pivotal moments of their corporate lifecycle to achieve their most critical business and legal goals.
Read more at:
